Compare JPMorgan Chase & Co (JPM) vs Tilray Brands Inc (TLRY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
JPMorgan Chase & Co vs Tilray Brands Inc — how do they compare? JPMorgan Chase & Co trades at $332.99 (market cap $880.98B), while Tilray Brands Inc trades at $3.54 (market cap $530.54M). The key difference: JPMorgan Chase & Co is far larger — about 1660.5× Tilray Brands Inc's market cap, and JPMorgan Chase & Co pays a 1.99% dividend while Tilray Brands Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold JPMorgan Chase & Co for 127 Days and Tilray Brands Inc for 31 Days on average.
| JPM | TLRY | |
|---|---|---|
Market Cap | $880.98B | $530.54M |
Volume | 7,721,661 | 9,099,075 |
Sector | Financials | Health |
52-Week High | $365.18 | $21.00 |
52-Week Low | $282.84 | $3.57 |
Typical Hold Time | 127 Days | 31 Days |
Enterprise Value | $1.82T | $684.46M |
Dividend Yield | 1.99% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
JPMorgan Chase (JPM) trades at $332.99, up 1.03% today, with a bearish technical signal but strong fundamentals. Recent earnings beat expectations in Q1 and Q2 2026, with revenue growth from $181.85B in 2025 to a projected $194.9B in 2026. The stock shows a P/E of 14.2 and ROE of 18.43%, supported by a 'Moderate Buy' analyst consensus and a $373.18 price target. News highlights CEO Jamie Dimon's economic warnings and upcoming Q1 earnings as key catalysts.
Outlook: JPM offers value with solid profitability and analyst upside, but risks include geopolitical tensions and cybersecurity threats. The stock's bearish technicals near support at $327 suggest caution, though institutional buying and high ROE provide stability. Investors should weigh strong fundamentals against macroeconomic headwinds highlighted in recent news.
TLRY trades at $3.54, down 4.71% on the day and near 52-week lows, reflecting persistent bearish sentiment. The stock shows negative technical momentum with consecutive earnings misses and widening losses despite revenue growth. Recent financials reveal a net loss of $2.19B for 2025, though analyst consensus maintains a $65.01 price target with 25% buy ratings. Business developments include new product launches and leadership changes under Tilray's expanded beverage portfolio.
Outlook remains challenged by profitability concerns and high debt, but potential cannabis regulatory shifts could catalyze recovery. Investment opportunity hinges on execution improvement and market expansion, while risks include sustained cash burn and competitive pressures in the cannabis sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About JPMorgan Chase & Co
JPMorgan Chase & Co. provides global financial services and retail banking. The Company provides services such as investment banking, treasury and securities services, asset management, private banking, card member services, commercial banking, and home finance. JP Morgan Chase serves business enterprises, institutions, and individuals.
Read more on JPM →About Tilray Brands Inc
Tilray is a Canadian company that grows and sells medical and recreational cannabis. In 2021, Aphria acquired Tilray in a reverse merger and adopted the Tilray name. Most of its sales come from Canada and international medical cannabis exports, while its U.S. business focuses on CBD products and alcohol.
Read more on TLRY →
